2CV Stock Chart & Stats
CHF2.37
CHF0.00(0.00%)
At close: 4:00 PM EDT
CHF2.37
CHF0.00(0.00%)
Day’s Range― - ―
52-Week RangeCHF2.28 - CHF2.60
Previous CloseN/A
Volume0.00
Average Volume (3M)N/A
Market Cap
CHF4.89B
Enterprise ValueCHF5.45K
Total Cash (Recent Filing)CHF99.51M
Total Debt (Recent Filing)CHF1.75B
Price to Earnings (P/E)48.6
Beta1.77
Next Earnings
Feb 23, 2027EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding1,942,370,600
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-7.33
Price to Book (P/B)4.36
Price to Sales (P/S)2.66
P/FCF Ratio19.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF3.41Price Target Upside43.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)<0.01
Revenue Forecast (FY)CHF28.01M
Bulls Say, Bears Say
Bulls Say
Recurring Chronic-care DemandConvaTec operates in chronic-care categories where consumables are replenished over time. Recurring utilization, reimbursement support and exposure to hospitals and home care provide a durable demand base and reduce reliance on one-off purchases.
Growth With Improving Operating MarginsSteady revenue expansion alongside materially higher operating margins indicates improving productivity and cost control. If sustained, this combination can support stronger operating leverage and earnings growth across the next several quarters.
Infusion Growth And Product PipelineStrong Infusion Care demand and clinically differentiated launches broaden the growth engine beyond mature categories. Capacity investment tied to long-term contracts and a progressing pipeline can reinforce market position and support the 6–8% medium-term growth target.
Bears Say
Higher Leverage And Moderate Cash ConversionGreater debt reliance reduces financial flexibility and increases sensitivity to earnings or interest-rate pressure. Moderate earnings-to-cash conversion further limits the speed at which ConvaTec can deleverage or fund growth without competing capital demands.
InnovaMatrix Structural SetbackThe collapse in InnovaMatrix sales and impairment signal a lasting reduction in the product's contribution, not merely a quarterly fluctuation. Although management expects it to become immaterial, the setback has weakened growth and margins while consuming management attention.
Multi-year FDA Remediation RiskA remediation program extending through 2027 creates persistent execution and compliance demands. While manufacturing and sales are currently unaffected, prolonged quality-system work can raise costs, divert resources and increase the risk of future operational or regulatory disruption.
2CV FAQ
What was ConvaTec’s price range in the past 12 months?
ConvaTec lowest stock price was CHF2.28 and its highest was CHF2.60 in the past 12 months.
What is ConvaTec’s market cap?
ConvaTec’s market cap is CHF4.89B.
When is ConvaTec’s upcoming earnings report date?
ConvaTec’s upcoming earnings report date is Feb 23, 2027 which is in 178 days.
How were ConvaTec’s earnings last quarter?
ConvaTec released its earnings results on Aug 04, 2026. The company reported CHF0.069 earnings per share for the quarter, beating the consensus estimate of CHF0.067 by CHF0.002.
Is ConvaTec overvalued?
According to Wall Street analysts ConvaTec’s price is currently Undervalued.
Does ConvaTec pay dividends?
ConvaTec does not currently pay dividends.
What is ConvaTec’s EPS estimate?
ConvaTec’s EPS estimate is 0.1.
How many shares outstanding does ConvaTec have?
ConvaTec has 1,942,370,600 shares outstanding.
What happened to ConvaTec’s price movement after its last earnings report?
ConvaTec reported an EPS of CHF0.069 in its last earnings report, beating expectations of CHF0.067. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of ConvaTec?
Currently, no hedge funds are holding shares in CH:2CV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ConvaTec Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF3.41 (43.80% Upside)
CHF3.41 (43.80% Upside)
Insider Transactions
Bought Shares
Worth £112.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.61%
12-Months-Change
Fundamentals
Return on Equity
1.33%
Trailing 12-Months
Asset Growth
3.64%
Trailing 12-Months
Company Description
ConvaTec
ConvaTec Group Plc operates as a global medical technology company, specializing in the creation, production, and worldwide distribution of a diverse array of healthcare products. Its offerings span critical areas, including advanced wound care, where it provides specialized dressings and skin care items for managing acute and chronic wounds that arise from conditions like diabetes, immobility, venous disease, traumatic injuries, burns, or surgical recovery. The company is also a key provider in ostomy care, delivering essential devices, accessories, and support services for individuals living with a stoma due to conditions such as colorectal cancer, inflammatory bowel disease, bladder cancer, and obesity. Beyond wound and ostomy solutions, ConvaTec's portfolio extends to continence and critical care. This includes intermittent urinary catheters and related products designed to assist individuals with urinary continence issues stemming from spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders. They also furnish equipment for intensive care units and hospital settings, alongside advanced systems for managing acute fecal incontinence and monitoring urine output and intra-abdominal pressure. Additionally, ConvaTec supplies various disposable medical devices, such as wound drainage systems, urine collection bags, airway management tools, gastroenterology tubes, and securement devices. The company manufactures disposable infusion sets for insulin pumps used in diabetes treatment, as well as for other continuous infusion therapies. These products reach pharmacies, hospitals, and both acute and post-acute healthcare providers directly, or through a network of distributors and wholesalers, catering to healthcare professionals, patients, and other manufacturers. Established in 1978, ConvaTec Group Plc is headquartered in Reading, United Kingdom.
2CV Stock 12 Month Forecast
Average Price Target
CHF3.41
▲(43.80% Upside)








